Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

BACKGROUND: Oncology therapy is becoming increasingly more expensive and challenging the affordability and sustainability of drug programmes around the world. When new drugs are evaluated, health technology assessment organisations rely on clinical trials to inform funding decisions. However, clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Kelvin, Nam, Seungree, Evans, Bill, de Oliveira, Claire, Chambers, Alexandra, Gavura, Scott, Hoch, Jeffrey, Mercer, Rebecca E, Dai, Wei Fang, Beca, Jaclyn, Tadrous, Mina, Isaranuwatchai, Wanrudee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955501/
https://www.ncbi.nlm.nih.gov/pubmed/31915169
http://dx.doi.org/10.1136/bmjopen-2019-032884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955501/
https://www.ncbi.nlm.nih.gov/pubmed/31915169
http://dx.doi.org/10.1136/bmjopen-2019-032884

Ejemplares similares